{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:25:41Z","timestamp":1781652341948,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DK105207"],"award-info":[{"award-number":["K23DK105207"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tenofovir disoproxil fumarate (<jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>) is an antiretroviral agent frequently used to treat human immunodeficiency virus (<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>). There are concerns regarding its potential to cause acute kidney injury, chronic kidney disease, and proximal tubulopathy. Although <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> can effectively suppress <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> after kidney transplantation, it is unknown whether use of <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>\u2010based antiretroviral therapy (<jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>) after kidney transplantation adversely affects allograft survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined 104 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>+ kidney transplant (<jats:styled-content style=\"fixed-case\">KT<\/jats:styled-content>) recipients at our center between 2001 and 2014. We generated a propensity score for <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> treatment using recipient and donor characteristics. We then fit Cox proportional hazards models to investigate the association between <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> treatment and 3\u2010year, death\u2010censored primary allograft failure, adjusting for the propensity score and delayed graft function (<jats:styled-content style=\"fixed-case\">DGF<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 104 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>+ <jats:styled-content style=\"fixed-case\">KT<\/jats:styled-content> candidates who underwent transplantation during the study period, 23 (22%) were maintained on <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>\u2010based <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> at the time of transplantation, and 81 (78%) were on non\u2010<jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>\u2010based <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>. Median age of the cohort was 48\u00a0years; 87% were male; 88% were black; and median <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 count at transplantation was 450 cells\/mm<jats:sup>3<\/jats:sup>. Median kidney donor risk index was 1.2. At 3\u00a0years post transplantation, primary allograft failure occurred in 26% of patients on <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>\u2010based <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> and in 28% of patients on non\u2010<jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>\u2010based <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> (<jats:italic>P<\/jats:italic>=.5). <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> treatment was not associated with primary allograft failure at 3\u00a0years post transplant after adjusting for <jats:styled-content style=\"fixed-case\">DGF<\/jats:styled-content> and a propensity score for <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> use (hazard ratio 2.12, 95% confidence interval 0.41\u201010.9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a large single\u2010center experience of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>+ kidney transplantation, <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> use following kidney transplantation was not significantly associated with primary allograft failure. These results may help inform management for <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>+ KT recipients in need of <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> therapy for adequate viral suppression.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12727","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T17:05:10Z","timestamp":1495127110000},"source":"Crossref","is-referenced-by-count":8,"title":["Association of tenofovir disoproxil fumarate with primary allograft survival in <scp>HIV<\/scp>\u2010positive kidney transplant recipients"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4722-6149","authenticated-orcid":false,"given":"Suzanne M.","family":"Boyle","sequence":"first","affiliation":[{"name":"Division of Nephrology Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Malat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hahnemann University Hospital  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera N.","family":"Harhay","sequence":"additional","affiliation":[{"name":"Division of Nephrology Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-3446","authenticated-orcid":false,"given":"Dong H.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pang","sequence":"additional","affiliation":[{"name":"Jefferson College of Pharmacy Thomas Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhura","family":"Talluri","sequence":"additional","affiliation":[{"name":"Division of Nephrology Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Nephrology Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany E.","family":"Bias","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hahnemann University Hospital  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ranganna","sequence":"additional","affiliation":[{"name":"Division of Nephrology Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden M.","family":"Doyle","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of Virginia School of Medicine  Charlottesville VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070726"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001197"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2008.508"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000071"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12147"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906768"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/378068"},{"key":"e_1_2_6_10_1","first-page":"1","article-title":"NIH consensus development statement on management of hepatitis B","volume":"25","author":"Belongia EA","year":"2008","journal-title":"NIH Consens State Sci Statements"},{"key":"e_1_2_6_11_1","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez\u2010Fernandez B","year":"2011","journal-title":"AIDS Res Treat"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/655681"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.167"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351f68f"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012080857"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1506-231"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2008.0232"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu617"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025195"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2012.0169"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ac620b"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1077558710361486"},{"key":"e_1_2_6_24_1","unstructured":"CDC.HIV and viral hepatitis. Available athttp:\/\/www.cdc.gov\/hiv\/pdf\/libraryfactsheetshivandviralhepatitis.pdf. Accessed January 28 2016."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001788"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000203187.49890.cc"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039229"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:12:00Z","timestamp":1695568320000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/tid.12727"],"URL":"https:\/\/doi.org\/10.1111\/tid.12727","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"article-number":"e12727"}}